Close Menu

NEW YORK (GenomeWeb) — Norwegian bioinformatics firm OncoImmunity announced on Monday that it has received €2.2 million ($2.5 million) in funding from the European Innovation Council to further develop its ImmuneProfiler personalized cancer medicine platform.

ImmuneProfiler applies machine learning to next-generation sequencing data to predict the immunogenic neoantigens in individual cancer patients that can serve as therapeutic targets and immunotherapy biomarkers, according to OncoImmunity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
17
Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.